URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$18.94
0.96 (5.34%)
▲
5d:
+4.53%
30d:
+0.64%
90d:
-18.26%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
URGN is down 3.7% this week, but smart money is accumulating calls. Top strike: $20 2026-05-15 with 392 OI. Call ratio: 99% View Scanner →
Strength: 6.7/10
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: URGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: URGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$25.21
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$15.65
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $18.94, which is considered oversold relative to its 30-day fair value range of $17.85 to $20.63. The stock's valuation (Forward PE: 20.5) is in line with its historical norms (19.5). At these levels, the market is pricing in 1.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is approaching resistance at $19.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: URGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.62 (+88.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is approaching resistance at $19.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: URGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $35.62 (+88.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$17.85 -
$20.63
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
96.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.3%)
- BULLISH: Trading 88.1% below Wall St target ($35.62)
- NEUTRAL: Market pricing in 1.7% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$17.85 -
$20.63
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$16.50
Resistance Level
$19.03
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.53
Wall Street Target
$35.63
(+88.1%)
Revenue Growth (YoY)
54.0%
Profit Margin
-139.8%
Valuation Premium vs History
+1.7% premium
PE vs Historical
20.5 vs 19.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.7%
(market-implied from PE analysis)
1-Year Target
$19.26
(+2%)
2-Year Target
$19.59
(+3%)
3-Year Target
$19.92
(+5%)
3-Yr Target (if PE normalizes)
(PE: 21→20)
PE COMPRESSION
$18.92
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: April 02, 2026 3:47 AM ET
Data refreshes hourly during market hours. Next update: 4:47 AM
Data refreshes hourly during market hours. Next update: 4:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason Drew Smith
SELL
7479 shares
2026-02-03
Mark Schoenberg
SELL
7373 shares
2026-02-03
Mark Schoenberg
SELL
10000 shares
2025-11-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 57 HOLD |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
